Last reviewed · How we verify
Dexmedetomidine prolonged sedation
At a glance
| Generic name | Dexmedetomidine prolonged sedation |
|---|---|
| Sponsor | Beijing Chao Yang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Prolonging Effect of Dexmedetomidine on Spinal Anesthesia Through Different Routes if Administrations (PHASE4)
- Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness
- Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With EVT on Long-term Prognosis in Patients With AIS (PPDET) (PHASE4)
- Dexmedetomidine for Prolonged Sedation in PICUs
- Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients (PHASE2, PHASE3)
- Dexmedetomidine Versus Propofol for Prolonged Sedation in Critically Ill Trauma and Surgical Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine prolonged sedation CI brief — competitive landscape report
- Dexmedetomidine prolonged sedation updates RSS · CI watch RSS
- Beijing Chao Yang Hospital portfolio CI